COOHIGH SIGNALFINANCIAL10-K

Cooper Companies experienced substantially higher interest expense alongside solid revenue growth, while adding specific trade war risk disclosures to their filing.

The dramatic increase in interest expense signals either significant new debt issuance or rising borrowing costs, which could pressure margins despite healthy revenue growth. The addition of explicit tariff and trade barrier risk language suggests management is increasingly concerned about geopolitical trade tensions impacting their global operations across 130+ countries.

Comparing 2025-12-05 vs 2024-12-06View on EDGAR →
FINANCIAL ANALYSIS

Cooper delivered solid fundamental performance with revenue growing 18.4% to $2.5B, supported by strong operating cash flow growth of 12.2% to $796.1M and higher R&D investment of 11%. However, interest expense increased substantially from $57.3M to $105.3M, indicating significant changes in the company's debt profile that investors should monitor closely. The overall picture shows a growing business with strong cash generation but emerging financial structure concerns.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+83.8%
$57.3M$105.3M

Interest expense surged 83.8% — significant debt increase or rising rates materially impacting earnings.

Revenue
P&L
+18.4%
$2.1B$2.5B

Revenue growing 18.4% — solid top-line momentum, watch margins for quality of growth.

Accounts Receivable
Balance Sheet
+15.6%
$717.0M$829.0M

Receivables grew 15.6% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
+12.2%
$709.3M$796.1M

Operating cash flow grew 12.2% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
+11%
$155.1M$172.2M

R&D investment increased 11% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2025-12-05
PRIOR — 2024-12-06
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 46 Item 7A.
The actual imposition or threats of tariffs, customs duties and fees by the U.S.
government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company s efforts to mitigate the effects of such tariffs or similar measures.
(Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments.
Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 45 Item 7A.
(Cooper, we or the Company), is a global medical device company with a mission to improve lives one person at a time.
We partner with health care providers worldwide to improve patient outcomes and deliver practice-building resources and training.
By listening closely to the healthcare providers and patients, we fulfill the needs of today while focusing on the opportunities of tomorrow through innovation and strategic investment.
In November 2019, the MiSight 1 day lens became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment, and in August 2021, CooperVision received Chinese National Medical Products Administration (NMPA) approval for use of the MiSight 1 day lens in China.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →